Core Viewpoint - Jingfeng Medical-B (02675) has successfully listed, with shares priced at HKD 43.24, raising a net amount of HKD 1.117 billion, and has seen a significant increase of 36.45% to HKD 59 per share at the time of reporting [1] Company Summary - Jingfeng Medical is a leading surgical robot company in China's medical device industry, focusing on the design, development, and manufacturing of surgical robots [1] - It is the first company in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [1] - Financial projections indicate revenues of HKD 48.04 million, HKD 160 million, and HKD 150 million for the years 2023, 2024, and the first half of 2025, respectively, with expected losses of approximately HKD 213 million, HKD 219 million, and HKD 89.087 million for the same periods [1] Industry Summary - According to Fangzheng Securities, the global IPO of Jingfeng Medical has attracted diverse and global cornerstone investors, reigniting capital interest in the laparoscopic robot sector [1] - The current penetration rate of laparoscopic surgical robots in China is less than 1%, significantly lower than the 21.9% in the United States, indicating substantial room for growth in domestic market share [1] - The market is predominantly led by the Da Vinci system, which holds over 40% of the market share, suggesting a strong potential for increased domestic production [1] - Continuous support from national policies and an accelerated opening of configuration licenses are contributing to the growing interest in this sector within the capital markets [1]